I n addition to guiding therapy, simultaneous DNA sequence analysis of tumor-normal pairs ("tumor-normal sequencing") reveals inherited cancer predisposition mutations in 3% to 12.6% of pediatric and adult patients with cancer. [1] [2] [3] [4] [5] [6] [7] It remains unknown, however, how many inherited mutations would be detected by multigene tumor-normal analysis compared with a traditional family history-based approach to genetic counseling and testing, and what the clinical implications of these findings would be. Selection for genetic testing is traditionally based on pathologic features of the tumor, age at diagnosis, family history of cancer, and other factors represented in clinical practice guidelines. [8] [9] [10] Studies have not determined whether inherited mutations found by tumornormal sequencing would have been detected by traditional approaches to selection for genetic testing. [1] [2] [3] [4] [5] This study presents the results of analyses of inherited ("germline") DNA performed in a prospective analysis of patients with advanced cancer tested by a targeted tumornormal sequencing panel as previously described. 11, 12 The goals of the study were to determine the incremental proportion of clinically actionable mutations detected by concurrent germline analysis in patients with cancer undergoing universal tumor profiling compared with selective germline testing based on existing practice guidelines and to assess the association of identified mutations with therapeutic management and targeted cancer prevention in family members.
Methods

Patient Cohort
The cohort comprised patients with advanced cancer at Memorial Sloan Kettering Cancer Center undergoing tumor and normal DNA sequencing using MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets), a 410-gene panel. 1, 11, 12 From May 2015, in the context of an institutional review board-approved protocol, patients with selected tumor types were prospectively offered secondary germline analysis after consenting to tumor genetic analysis. Germline analysis included 76 genes on the MSK-IMPACT panel associated with hereditary cancer predisposition, including all cancer-predisposing genes identified in the American College of Medical Genetics and Genomics guidelines. [13] [14] [15] Nine mutation carriers were included in a prior study, 1 and 23 and 51 mutation carriers were included in recent series of prostate cancer, 16, 17 although clinical annotation including family history and treatment information was not available for those articles.
Ascertainment, Consent, Sequencing, Variant Calling, and Results Reporting
Through their physicians, patients were offered participation in a research study, using a video consent aid explaining risks and benefits of testing for inherited mutations (germline testing). Eligibility was restricted to those who also consented to tumor sequencing, with emphasis on patients with advanced (stage III-IV) disease; however, physicians had discretion for patient referral. Genetic testing reports were issued to the medical record, and individuals with pathogenic or likely pathogenic variants (henceforth referred to as "pathogenic variants") were invited for genetic counseling where at-risk family members were identified (eAppendix 1 in Supplement 1). Tumor DNA and nontumor DNA were sequenced and variants were reported as described previously 11 (eAppendix 2 in the Supplement 1). Variants were interpreted based on American College of Medical Genetics and Genomics criteria 18 by a clinical molecular geneticist or molecular pathologist; variants of unknown significance (eTable in Supplement 2) were not included in clinical reports. Loss of heterozygosity (LOH), defined as loss of the normal allele in the tumor at the locus of the inherited mutation, was assessed by the FACETS algorithm as published previously 19 ; hypermutated status was defined as 20 or more mutations; and microsatellite instability high (MSI-H) was defined as more than 10% of loci on the MSK-IMPACT panel demonstrating microsatellite instability. 20 In this study, not all pathogenic mutations (associated with disease causation) were considered clinically actionable. Clinical actionability of pathogenic variants was defined by evidence for their utility in cancer prevention (eAppendix 3 in Supplement 1) and/or potential utility as therapeutic targets. For this study, all germline mutations of established low, moderate, or high risk (penetrance) were considered clinically actionable [8] [9] [10] 16, 21, 22 (eTable 1 in Supplement 1). Mutations were classified as having high penetrance (relative risk >4), moderate penetrance (relative risk 2-4), or low penetrance (relative risk <2) as well as being recessive or of uncertain clinical actionability based on known disease-associated risks and current modeling. [8] [9] [10] 16, 21 effects of population stratification. Ashkenazi ancestry was determined by self-report of religious preference, via a list of choices, at the time of registration or by specific report of Eastern European Jewish background of relatives at the time of genetic counseling. Race was self-reported by fixed categories at the time of registration. Three-generation family history information was assessed at the time of results communication or from records at the time of genetic testing. Published guidelines and syndrome-specific genetic testing algorithms [8] [9] [10] [23] [24] [25] were used to determine which genetic tests would be indicated based on tumor histologic features, bilaterality, multiple metachronous cancers, age at onset of cancer, family history of cancer (including age at which relatives were affected), and self-reported Ashkenazi ancestry. Where indicated, multigene panels (eTable 2 in Supplement 1) were considered standard of care and were applied using decision rules based on published guidelines (eAppendix 4 in Supplement 1). A pathogenic variant in secondary analysis was considered incremental if it would not have been detected by testing that would have been ordered based on application of these decision rules, with additional decision rules for cases harboring 2 variants (eAppendix 5 in Supplement 1).
Adjustment for Founder Mutations and DNA Repair Genes
To adjust for effects of founder mutations, a set of Ashkenazi and European founder mutations in BRCA1/2, APC, MSH2, MSH6, CHEK2,orMUTYH were included in the overall analysis but also identified so as to allow subset analysis (eBox in Supplement 1). Mutations in ATM, BAP1, BARD1, BRCA1/2, BRIP1, CHEK2, FAM175A, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, and RAD51D recently associated with advanced prostate cancer 16 were coded for separate analysis of patients with advanced prostate cancer, and to assess patients potentially amenable to targeted therapies.
Statistical Analysis
Variant frequencies in cases were compared with allele frequencies in noncancer controls from public databases and stratified by European and Ashkenazi subsets. [26] [27] [28] [29] [30] Allele frequencies were compared by Fisher exact 2-sided binomial test in R version 3.3 software (R Foundation) using RStudio version 0.99.903 (RStudio). To estimate findings resulting from a different case mix, tumor type-specific rates of pathogenic variants were multiplied by cancer rates in the general population 31 as well as rates of discordant variants observed in a separate ascertainment 1 (eAppendix 6inSupplement 1). Where proportions are presented, 95% confidence intervals were derived. Clinical variables were compared with regard to genetically defined subsets, mutational load as measured by number of somatic mutations, and time from diagnosis to tumor-normal analysis for metastatic disease, using 2-sample t test for independent samples, with 2-tailed P values significant at P < .05. Rates of incremental findings were compared between subsets by Fisher exact test, and proportions of germline findings were compared by stage of disease using χ 2 test.
Results
Cohort Characteristics
As part of an institutional review board-approved protocol, from January 1, 2014, until 
Variants Detected
Of the 1040 patients undergoing secondary germline analysis, 205 patients (19.7%) harbored pathogenic variants conferring cancer predisposition. Of the 205 patients with pathogenic variants, 182 carried clinically actionable mutations of high (n = 97), moderate (n = 52), or low (n = 33) penetrance, 8 were carriers of variants associated with recessive syndromes, and 15 carried variants in genes of unproven clinical actionability. Had all individuals been screened for populationspecific founder mutations in addition to guideline-directed testing, the proportion of incremental clinically actionable findings would have declined to 57 of 182 patients (31.3%; 95% CI, 25.0%-38.4%). Had patients with prostate cancer also been screened with a panel of DNA repair genes, the resulting proportion of findings considered incremental would be 35 of 182 patients (19.2%; 95% CI, 14.2%-25.6%) or 3.4% (95% CI, 2.4%-4.7%) of the 1040 cases overall (eTable 4 in Supplement 1). The highest proportion of actionable findings that would not have been detected based on clinical guidelines were observed in biliary, prostate, colorectal, renal, and pancreatic tumors (eTable 4 in Supplement 1). Table 3 shows all cases with incremental actionable findings, excluding known founder mutations, which would not have been detected using guidelinedirected approaches for high-penetrance mutations (BRCA2, CDKN2A, PALB2, VHL, SDHA, MSH2, MSH6, and BAP1), moderate-penetrance mutations (CHEK2, ATM, MITF, BRIP1, and RAD51D), and low-penetrance mutations (APC, MUTYH). Twenty-two percent of germline BRCA1/2 mutations (13 of 59 
Tumor-Germline Correlations
In the 205 patients with a pathogenic variant, 93 of 170 tumors (54.7%) showed LOH or a pathogenic somatic second mutation in the same gene as the pathogenic variant. Of 180 evaluable pathogenic variants in 170 tumors, 82 variants showed LOH in the tumors and 13 tumors demonstrated a loss-offunction mutation or a previously reported deleterious missense variant. 32,33 Concurrent somatic LOH or a second mutation at the same locus accompanied the germline mutation in 37 of 48 evaluable tumors (77.1%) in patients with BRCA1/2 germline mutations, 9 of 12 patients (75.0%) with mismatch repair gene variants, and 13 of 36 patients (36.1%) with germline CHEK2 variants, including 5 of 10 patients (50.0%) with the founder CHEK2 c.1100delC variant. Of the 103 pathogenic BRCA mutations identified in the tumors of the 1040 patients in this study, only 59 were germline in origin, whereas 44 were detected in the tumor. A hypermutated tumor profile (defined as >20 somatic mutations) or MSI-H (defined as >10% of loci by MSIsensor 20 ) was observed in 51 of 1040 patients (4.9%).
Germline pathogenic variants in mismatch repair genes were identified in 12 of these 51 patients (23.5%). Two additional patients with germline MSH6 truncating mutations had tumors that were not hypermutated or MSI-H by MSIsensor (1 with renal cell cancer and 1 with prostate cancer). Among the hypermutated or MSI-H cases, 14 of 51 (27.5%) fulfilled clinical criteria for Lynch syndrome (revised Bethesda guidelines and/or Amsterdam II criteria); 6 of 12 patients (50.0%) with an MSI-H tumor and an identified germline pathogenic variant in a mismatch repair gene met these criteria. Of the 14 cases with germline mismatch repair mutations, 6 were incrementally detected by germline analysis in the absence of a family history diagnostic of Lynch syndrome, including 3 patients with bladder cancer and 3 with prostate cancer. Of these 6 cases, 3 demonstrated LOH or a second somatic mutation (Table 3) .
Discussion
This study identified clinically actionable inherited mutations in 17.5% of patients with advanced cancer, compared with 3% to 12.6% in prior series. [1] [2] [3] [4] [5] [6] [7] Of the 1040 patients, 101
(9.7%) would not have been detected using clinical guidelines, which represented 55.5% of the total of 182 patients with actionable findings in the series. Germline findings led to discussion or initiation of change to targeted therapy in 38 (3.7%) of the 1040 patients tested and predictive testing in the families of 13 individuals (1.3%), including 6 for whom genetic evaluation would not have been initiated by guideline-based testing. f The MSH6 variant in this case is a founder variant (see eTable in Supplement 3) and was not counted toward the total of high-penetrance cases with nonfounder variants, but it is included here to illustrate one of the incremental cases with hypermutation status and MSIsensor data.
g Refers to a second nonincremental variant. The prevalence of germline variants in a clinical setting will be affected by stage, case mix, ethnic ancestry of the population, and methods of variant classification. There was a significantly greater overall prevalence of germline mutations observed in patients with metastatic disease, although the proportion of germline findings that were incremental to predictions based on family history (approximately 50%) was similar in metastatic and nonmetastatic disease. This interesting association may reflect more aggressive biological features (eg, via greater mutational load of deleterious variants) or improved chance of survival with metastases in those with germline mutations. However, in the cohort studied here, there was no association of inherited mutations with increased tumor mutational load or difference in time from diagnosis to metastatic disease; further molecular profiling and prospective studies of treatment response may provide an explanation for the increased prevalence of germline mutations in metastatic disease. In this series, there was an abundance of late-stage prostate, pancreatic, renal, and breast cancers in which germline variants were more frequent, probably accounting for the higher observed prevalence of pathogenic variants found here compared with prior studies. While these findings reflect the experience at a referral cancer center, had the case mix more closely resembled population cancer incidence rates, the proportion of incremental findings would have been 49.1%. Had the entire cohort been screened for ancestry-specific (Ashkenazi and northern European) mutations, the proportion of incremental actionable findings would have been 31.3%, approximating the rate in a hypothetical cohort with no population diversity. However, if family history assessment by clinicians is less complete than the 3-generation information used in this analysis, the proportion of apparent incremental findings may be higher in practice. Thus, guideline-based testing will fail to detect a third to half (31.3%-55.5%) of genetic findings found by tumor-normal sequencing, taking into account case mix, disease stage, and ethnic ancestry.
The complementary role of tumor and germline sequencing was exemplified by colon and breast cancer testing. Tumornormal testing was able to diagnose Lynch syndrome in patients who would not otherwise have been tested. The sensitivity of tumor-derived hypermutation or MSI-H status for detection of Lynch syndrome was 85.7%, with germline sequencing resulting in the diagnosis of Lynch syndrome in an additional 2 patients, 1 of whom would not have been diagnosed by family history. Half of the 12 cases with pathogenic variants in mismatch repair genes in the setting of a hypermutated or MSI-H tumor would not have met guidelinebased criteria for tumor-directed immunohistochemical analysis. For breast cancer cases, had tumor-only testing been performed, approximately 40% of patients with BRCA1/2 variants detected with tumor sequencing would have been referred for a germline confirmation test that would have been negative; conversely "subtraction" of germline from tumor DNA sequence would have obscured 59 germline BRCA1/2 cases. These observations support the rationale for combined tumor-normal sequencing. 3, 34 Although epigenetic mechanisms of loss of the second allele may also exist, concurrent somatic alterations in the same gene or LOH in matched tumors support the pathogenic role of many of the germline variants observed in nonsyndromic settings. For example, germline CHEK2 mutations were observed in 6 patients with renal cancer; the second allele was mutated in 3 of 5 evaluable tumors. Among novel nonsyndromic associations seen here, mutations in CHEK2 were enriched in prostate and pancreas cancers, MUTYH heterozygous mutations were enriched in prostate cancer, and mutations in MSH6, BARD1, PALB2, MITF, and SDHB, were observed absent the typical family history associated with these genes. Other unanticipated findings reported here will require further functional and genetic epidemiologic genomic exploration, including the observation of the recurrent mutation FH c.1431_1433dupAAA (p.Lys477dup) and RECQL4 lossof-function variants. [35] [36] [37] To our knowledge, this study marks the first large-scale effort to return germline findings in the context of tumornormal sequencing to patients. Such an approach in patients with advanced cancer was found to uncover potentially actionable germline variants that would not be detected using existing guidelines for genetic risk assessment. Less resourceintensive strategies than tumor-normal sequencing could be applied but would result in lower sensitivity. For example, testing all patients for a dozen DNA repair genes and several APC and MUTYH founder mutations, combined with standard phenotypic assessment, would have detected 92.3% of patients with clinically actionable germline variants.
This study has several limitations. Among these is the lack of sufficient follow-up to assess the effect of the genetic in- formation on patient or family outcomes, including potential harms due to false-positive results of screening. In addition, there was physician discretion for referral for tumor sequencing, potentially favoring enrollment of those who may have been eligible for targeted therapies. The usual care comparator in this study was synthetic and not the actual yield of testing a population according to guidelines. Also, interpretation of detailed family history information was by expert reviewers using reproducible but complex algorithms. In addition, the study had unique demographic characteristics and case mix. These factors will limit generalizability of findings to a community practice environment, where germline testing panels are also being introduced.
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Conclusions
In this referral population with selected advanced cancers, universal sequencing of a broad panel of cancer-related genes in paired germline and tumor DNA samples was associated with increased detection of individuals with potentially clinically significant heritable mutations over the predicted yield of targeted germline testing based on current clinical guidelines. Knowledge of these additional mutations can help guide therapeutic and preventive interventions, but whether all of these interventions would improve outcomes for patients with cancer or their family members requires further study. Patients were ascertained by treating physicians according to a research protocol 12-245 in which eligibility included any patient with cancer treated at MSKCC who had previously consented to "Part A" of the study (tumor genotyping). Patients were enrolled without consideration to prior germline testing. (Indeed, prior genetic counseling was reported in 53 of the 205 cases who were found during the study to harbor mutations; in 30 cases the study confirmed the already known high penetrant mutation, and in 3 of these cases identified a second (incremental) variant in a low or moderate penetrant gene.)
Pre-test counseling involved discussion by the ordering physician-investigator and supplemented by an educational video. The video-assisted consent process included the elements covered in traditional pre-test counseling (concepts of inheritance, purpose of analysis, potential implications for family members, questions about genetic discrimination, test limitations). While uptake was not an element in the study, a pilot project of a subset of cases indicated that the level of uptake was in excess of 90% consenting to germline return of results as well as somatic (tumor) sequencing. The enrolling physicians were responsible for transmitting the test result to the patient once the results were available, with the recommendation to refer to post-test counseling.
Patients who declined post-test counseling, according to the protocol, received the results from their physicians. Additional follow-up by clinical genetics staff was provided stating the availability of genetic counseling, and the potential implications of a germline result to the patient and family. For patients who came for genetic counseling after receiving the results from their physicians, the post-test counseling was not uniformly modified to account for a different pre-test counseling model, but was individualized depending on the extent of patient's knowledge and understanding of the test results already disclosed to them by physicians.
Variants of uncertain significance (VUS) were not communicated in this study. However, the clinical laboratory providing this testing (called IMPACT) headed by Board-certified lab directors, reviewed VUS on a regular basis. Any variants initially classified as a VUS that were re-classified to likely pathogenic or pathogenic variants were communicated to the ordering physicians and/or Clinical Genetics Service and patients via amended clinical reports.
All of the germline-and tumor-sequencing-performed in this study was completed as part of a research study. There was no billing to patient for genetic testing, or pre test counseling. Individuals with positive test results coming for post test counseling were billed for post test counseling and consultation as appropriate and family members invited for follow up testing and counseling as per standard guidelines. Insurance or third party coverage for testing was not requested as it would not have been included in coverage for many cases and would have served to negatively impact and potentially bias ascertainment.
eAppendix 2. Methods for variant calling.
Germline variants from the .bam file of the non-tumor DNA sequence with mapping and base quality scores of >20 were called using MuTect 1 and GATK Haplotypecaller 2 using 25% variant frequency and 20X coverage thresholds. All variants with <1% population frequency in the Exome Aggregation Consortium (ExAC) database were interpreted. Copy number variations were assessed using an in-house developed pipeline and were confirmed with an additional laboratory tests 3 .
eAppendix 3. Definitions of high, moderate, low penetrance variants, variants associated with recessive syndromes, and variants of uncertain clinical actionability.
Mutations were classified by penetrant status utilizing known disease risks and current modeling [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
BAP1, BRCA1/2, CDH1, CDKN2A, FH, FLCN, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2
, SDHA/B, and VHL were considered "high penetrant", according to the consensus guidelines and known associations with high-penetrance hereditary cancer predisposition syndromes [5] [6] [7] 9, [14] [15] [16] [17] [18] [19] . While PALB2 has been referred to as moderate penetrance in some series, the OR of 5.3 in the recent analysis by Easton et al places PALB2 in the higher penetrant category, defined by OR >4.0 14 . Mutations in ATM, BRIP1, CHEK2 (other than p.Ile157Thr), MITF, NBN, and RAD51D genes were considered "moderate penetrance," defined as OR = 2-4. The role of ATM, CHEK2, and BRIP1, RAD51D as moderate penetrance genes associated with increased risk of breast or ovarian cancer, respectively, has been well established 5, [11] [12] [13] [14] [15] , while the evidence regarding specific cancer risks associated with mutations in NBN and MITF is still emerging. NBN is considered a moderate penetrance predisposition gene associated with increased breast cancer risk, based largely on data related to a protein-truncating variant, c.657del5, shown by meta-analysis of 10 studies to have an OR of 2.7 14, 15 , with a single recent casecontrol study showing an association with pancreatic cancer (OR: 3.80) 8 . It remains unclear if other mutations of NBN will also show these same levels of disease risk, but for the purposes of this analysis the classification of NBN as moderate penetrance by Easton et al 14 was observed. While the evidence regarding the level of risk associated with MITF mutations in kidney cancer has not been conclusive 7 , recent studies support the originally described status of MITF as a moderate penetrance predisposition gene in melanoma (OR 3.3 9 ; OR: 2.85 10 ), with recommendations given for heightened surveillance. BRIP1 is also characterized as an ovarian cancer risk gene by NCCN, with OR's in the range of 8.13-11.22 11, 12, 16 . APC p.Ile1307Lys and heterozygous mutations in MUTYH were coded as "low penetrant" variants (OR >1 but generally 2 or lower).
RECQL4 was classified as of unknown risk as a heterozygous variant, although of proven association with recessive syndromes, while FAM175A, BARD1 and RAD50 mutations and CHEK2 Ile157Thr were classified as pathogenic mutations of uncertain clinical actionability in the preventive setting, and/or unproven but of potential utility as therapeutic targets. During the course of the study an in frame insertion in the fumarate hydratase gene (FH c.1431_1433dupAAA p.Lys477dup; rs367543046, chr1:241661227 A/ATTT) was found to recur among 5 individuals, 1 with pancreatic (diagnosed age 56) and 4 with prostate cancer (diagnosed ages 59, 65, 65, 71), 4 of whom were of selfidentified Ashkenazi ancestry. Because none of these cases fulfilled diagnostic criteria for or had a family history of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC), for the purposes of the current analysis, this variant was classified as correlated with recessive FH deficiency, but of uncertain clinical actionability with respect to HLRCC, until further genetic epidemiologic evidence is available. For patients meeting criteria for genomic testing as established by NCCN, ACMG, or syndrome-specific guidelines where NCCN or ACMG not available, [15] [16] [17] [18] [19] [20] and/or based on characteristic morphology associated with the known syndrome), disease-specific panel testing (Breast, Ovarian, Breast Ovarian, Colorectal, Polyposis, Pancreatic, Renal, Paraganglioma panels) were deemed appropriate according to the following rules: 1) Patients diagnosed with the tumor type corresponding to the disease-specific panel (breast, ovarian, colon, pancreatic or renal cancer) when there was no known mutation in the family that would fully account for the observed history. If there was a known mutation in the family, then the patient offered targeted gene test only.
2) Patients diagnosed with the tumor type corresponding to the disease-specific panel (breast, ovarian, colon, pancreatic or renal cancer), meeting criteria for >1 predisposition syndrome known to be associated with the tumor type and included in one of the panels When criteria for testing were met solely based on Ashkenazi ancestry (e.g. late onset isolated breast cancer and Ashkenazi ancestry), targeted gene testing was performed as indicated by guidelines. Panels were not considered appropriate for patients with non-syndromic tumor types who met diagnostic criteria for syndrome testing based on the family history, in which case directed gene testing was offered for breast ovarian, Li-Fraumeni or other syndromes as indicated.
Cases meeting testing criteria for specific syndromes based on histology alone were offered testing based on tumor morphology (e.g. fumarate hydratase for hereditary leiomyomatosis renal cell cancer syndrome). For classification of number of patients with variants in genes of various penetrances, if the case had 2 variants with different penetrance levels, then the case was classified according to the higher penetrant variant. In all analyses no cases were counted more than once. In the analysis of incremental findings not predicted by clinical guidelines, when accounting for cases with both an actionable incremental variant and one that was not actionable or incremental, then those cases were counted as having an actionable incremental finding. If a case had both a low penetrant founder mutation and a higher penetrance non-founder mutation that was incremental to phenotype based analysis, that case was scored as having the higher penetrant variant and was not subtracted from total of incremental findings minus founder mutations. For cases with two variants where one variant that was predicted by phenotype and was of higher penetrance than a second variant that was incremental, for the analysis of incremental findings by penetrance class, the lower penetrant incremental variant was scored and counted in this analysis. In cases where a second cancer was diagnosed after the first, but the genetic analysis was performed on the first cancer, then that case was considered as having a primary diagnosis of the tumor type at time of genetic analysis. In the series, 15 cases had more than one variant, including 11 high penetrant cases also with a moderate, low, or recessive mutation, 2 moderate penetrant cases also with a low penetrant mutation, and 2 low penetrant cases with another low penetrant or variant of uncertain actionability. eAppendix 6. Supplemental statistical methods.
Adjustment of incremental rates
Adjustment for Case Mix
To estimate the proportion of incremental variant detection in an unselected population of cancer patients, observed tumor type-specific rates of pathogenic or likely pathogenic genetic variants (P/LPGV) were multiplied by cancer rates based on general population incidence 21 , and then multiplied by tumor type-specific rates of incremental variants observed or imputed from a separate ascertainment 22 , and summed to give expected rates of incremental findings given case mix adjustment for purposes of estimated adjusted rates given a different case mix (Discussion section).
Case mix adjustment for the cohort was performed by deriving proportion of cancers of type A, B, C, etc in the study cohort that would have been expected using distributions of (2016) 22 , which utilized a separate but similarly ascertained patient population at the same institution and identical methods of genotyping and variant interpretation, V A was measured directly and is taken from Figure 3 of Schrader et al., while I A was approximated as the number of discordant P/LPGV.
Comparison of Germline Data to Public Databases.
To assess association of specific variants and tumor phenotypes, population allele frequencies were extracted from the exome aggregation consortium (ExAC) data 23 accessible both as a download and through a browser 24 excluding cases derived from cancer patients as part of The Cancer Genome Atlas (TCGA). Further details of ExAC are available at http://exac.broadinstitute.org/faq. Data were stratified by European and Ashkenazi subsets 23, [25] [26] [27] , Comparisons of allele frequencies in cases of Ashkenazi ancestry were restricted to a control population of Ashkenazi ancestry 28 . Allele frequencies were compared by Fisher Exact test in R version 3.3 using RStudio Version 0.99.903. Where proportions are presented, 95% confidence intervals were derived. Comparison of clinical variables in genetically define subsets (e.g. age, interval from diagnosis to genetic analysis) were compared by two sample t-test for independent or correlated samples, as appropriate. Comparisons of rates of incremental findings between subsets was by Fisher's Exact test.
Correlation of Germline Mutation Status and Mutational Load and Time to Metastases
In order to determine if there was an association between presence of germline P/LPGV and tumor burden of somatic mutations, a comparison was made between germline P/LPGV and total burden of somatic mutations. Burden of somatic mutations was defined as the number of single nucleotide variants and indels, and did not include copy number variants or silent mutations. In this global analysis, cases of germline mismatch repair gene mutations were included in the P/LPGV positive group, as well as somatic MLH1 promotor hypermethylation included in the P/LPGV negative group. Each case with a P/LPGV was given a numerical score representing the sum of the tumor P/LPGV's and compared to the scores of cases without P/LPGV by two sample t-test for independent samples, with two tailed p value. For the analysis of time to diagnosis we determined the average time between initial diagnosis of malignancy as recorded in the medical record and time to presentation with metastatic disease for tumor normal sequencing at our institution. Comparisons were by two sample t-test for independent samples, with two tailed p values 
Tumor syndrome listed in the headers for each column, and gene listed as the header for each row with "x" denoting inclusion in the syndrome-specific panel. This table reflects the total number of incremental clinically actionable mutations, and the number of those mutations minus founder mutations in each tumor category and categorized by penetrance. For the subset of prostate cancer cases only, a further subtraction is made for cases with variants in DNA repair genes associated with advanced prostate cancer. In the analysis of incremental findings not predicted by clinical guidelines, when accounting for cases with both an actionable incremental variant and one that was not actionable or incremental, then those cases were counted as having an actionable incremental finding. Decision rules for determination of penetrance levels, clinically actionable status and incremental status for cases with more than one variant are specified in eAppendix 5. 
